Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 06:09:21 2024-06-25 EDT 5-day change 1st Jan Change
95.78 CHF -0.24% Intraday chart for Novartis AG +2.90% +12.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Foreign banks target Switzerland after UBS takeover of Credit Suisse RE
NOVARTIS AG : Barclays reaffirms its Sell rating ZD
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax DP
Factbox-European companies cut jobs as economy sputters RE
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 DP
Novartis: towards the filing of a buyout offer for MorphoSys CF
MorphoSys Set to Delist Following Acquisition by Novartis MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis MT
Biotech company Morphosys will soon disappear from the stock exchange RE
EU regulator mandates label updates on CAR-T cancer therapies RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists RE
Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe DJ
Novartis and others face Italy antitrust probe over eye drug RE
Three newcomers to the MDax - Rational, TUI and Traton move up RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout DJ
The odds of rates getting cut in 2024 may be better than you think Our Logo
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation MT
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107.5 USD
Average target price
110.3 USD
Spread / Average Target
+2.66%
Consensus
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating